Recent advancements have shown that plasma biomarkers, such as Aβ42 and phosphorylated tau (pTau217), are reliable indicators of AD pathology, offering advantages such as being less invasive, cost-effective, and time-efficient [152–155]. Here, MAPT is linked to Alzheimer disease.